UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13A-16 OR15D-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
Dated October 14, 2015
Commission File Number001-35428
PRIMA BIOMED LTD
(Exact Name as Specified in its Charter)
N/A
(Translation of Registrant’s Name)
Level 7, 151 Macquarie Street
Sydney, 2000 New South Wales, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.
Form20-F x Form40-F ¨
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b) (1): ¨
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b) (7): ¨
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: October 14, 2015
| | | | |
| Prima BioMed Ltd |
| |
| By: | | /s/ Marc Voigt |
| | Name: | | Marc Voigt |
| | Title: | | Chief Executive Officer |
2
EXHIBIT INDEX
| | |
Exhibit | | Description of Exhibit |
| |
| 99.1 | | Information Required Under Listing Rule 3.10.5A |
3
